Comparative Efficacy of Antidepressants

Drugs

Volumn 43, Issue 2, 1992, Pages 11-23

  Kasper, S ^a   Fuger, J ^a   Moller H J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

CARDIOTOXICITY; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DROWSINESS; GLAUCOMA; HEART DISEASE; NAUSEA; PANIC; PERSONALITY DISORDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEDATION; SUBSTANCE ABUSE; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; COMPARATIVE STUDY; DEPRESSIVE DISORDER; HUMAN; MENTAL DISORDERS; NEUROTRANSMITTER UPTAKE INHIBITORS; SEROTONIN;

EID: 0026724803     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199200432-00004     Document Type: Article

References (108)

1. Placebo controlled double-blind trial of fluvoxamine maleate in the obese
2. Clinical multicenter study of citalopram compared double-blindly with mianserin in depressed patients in Finland
3. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline
4. A double-blind, placebo-controlled dose-finding study with sertraline
5. Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study
6. Double-blind comparison of fluvoxamine and imipramine in depressed patients
7. Fluvoxamine versus dothiepin: a double-blind study in elderly depressed patients
8. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients
9. Reduction of prefrontal cortex glucose metalbolism common to three types of depression
10. Clomipramine in obsessive-compulsive disorder. Further evidence for serotonergic mechanism of action
11. Citalopram versus maprotiline: a controlled clinical multicentre trial in depressed patients
12. An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine
13. Peripheral and central mechanisms of action of serotoninergic anorectic drugs
14. Preliminary results: placebo-controlled data on fluvoxamine maleate, a serotonergic antidepressant
15. Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine and placebo
16. Four new atypical antidepressants (trazodone, mianserin, nomifensine, caroxazone): results of controlled trials
17. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder
18. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behaviour
19. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients
20. A placebo and imipramine controlled study of paroxetine
21. A comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder
22. Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine
23. Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalized depressed patients
24. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study
25. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
26. Pyschopharmacological treatment of avoidant personality disorder
27. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression
28. Citalopram versus mianserin. A controlled double-blind trial in depressed patients
29. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing
30. A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine
31. A double-blind placebo-controlled study for fluvoxamine and imipramine in depression
32. Disparity of thyrotropin (TSH) and prolactin responses to TSH-releasing hormone in obesity
33. The efficacy profile of paroxetine, a new antidepressant, compared with imipramine and placebo
34. Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives
35. A double-blind multicenter study comparing the safety and efficacy of sertraline with placebo in major depression
36. Efficacy of fluoxetine in outpatients with major depression
37. Fluoxetine versus amitriptyline in adult outpatients with major depression
38. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder
39. Paroxetine in the the treatment of major depression
40. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression
41. Fluoxetin-induced weight loss in overweight non-depressed humans
42. Pattern analysis of antidepressant response to fluoxetine
43. Efficacy of the new generation antidepressants — a statistical metaanalysis
44. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients
45. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study
46. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo
47. A double-blind comparison of citalopram (Lu 10–17) and amitriptyline in depressed patients
48. A double-blind controlled clinical trial of comparing fluvoxamine with imipramine
49. A double-blind multicentre study of paroxetine versus clomipramine in depressed elderly patients
50. A doubleblind clinical trial of fluvoxamine and imipramine in patients with primary depression
51. Fluoxetine treatment of anorexia nervosa: an open clinical trial
52. Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial
53. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression
54. Serotonin and symptom severity in eating disorders
55. Plasma levels of fluvoxamine and maprotiline and clinical response in major depression
56. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression — results of a double-blind study
57. Fluvoxamine and clomipramine in depressed patients: a double-blind clinical study
58. Fluoxetine vs amitriptyline in the treatment of depressed outpatients
59. Behandlungsergebnisse mit Fluoxetin im Vergleich mit Amitriptylin bei ambulanten und stationaren Patienten im Rahmen von Doppelblindstudien (Gesamtanalysen)
60. Treatment of major affective disorder with fluvoxamine
61. A comparative trial of a new antidepressant, fluoxetine
62. Use of a serotonin reuptake inhibitor, fluoxetine, in the treatment of obesity
63. Methodenkritik des Wirksamkeitsnachweises antidepressiver Pharmakotherapie
64. A double-blind placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression
65. Paroxetine in the treatment of depression: a double-blind multicenter study versus mianserin
66. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
67. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder
68. Effects of fluoxetine on the intragastric self administration of ethanol in the alcohol proferring P line of rats
69. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers
70. The serotonin uptake inhibitor citalopram attenuates ethanol intake
71. Adverse reactions in connection with zimelidine treatment: a review
72. Fluoxetine in borderline personality disorder
73. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients
74. The efficacy of fluvoxamine in patients with severe depression
75. A double-blind randomized comparison of fluvoxamine with mianserin in depressive illness
76. Fluvoxamine treatment of obsessive-compulsive disorder
77. The short- and long-term efficacy of paroxetine HCI: B. Data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo
78. Ambulante antidepressive Therapie. Eine multizentrische Doppelblindstudie
79. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder
80. Antidepressant efficacy of sertraline: a double-blind placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression
81. Characteristics of responders to fluoxetine
82. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients
83. Die Wirklatenzhypothese von Antidepressiva: Vergleiiiich zwischen Fluvoxamin und Maprotilin
84. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression
85. Biochemical correlates of temperament dimensions
86. A comparison of the antidepressant action of citalopram and amitriptyline
87. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder
88. A double-blind comparative clinical trial of citalopram versus maprotiline in hospitalized depressed patients
89. Serotonin and alcohol interrelationships. 16th collegium internationale neuropsychopharmacologicum congress satellite conference: new findings with anxiolytic drugs, Munich, FRG
90. Fluvoxamine in the treatment of the older depressed patients: double-blind, placebo-controlled data
91. Clinical and biochemical effects of selective serotonin-uptake inhibitors in anxiety disorders
92. Carbohydrate craving, mood changes, and obesity
93. A controlled comparison of fluoxetine and amitriptyline in depressed outpatients